Indaptus Therapeutics Inc (INDP)vsRegeneron Pharmaceuticals Inc (REGN)
INDP
Indaptus Therapeutics Inc
$2.21
+2.79%
HEALTHCARE · Cap: $414.47M
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.11%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
INDP
Avoid17
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INDP.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : INDP
INDP has a balanced fundamental profile.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : INDP
The primary concerns for INDP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
INDP profiles as a value stock while REGN is a growth play — different risk/reward profiles.
INDP carries more volatility with a beta of 1.27 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 17/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Indaptus Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Indaptus Therapeutics Inc. is an innovative biotechnology company dedicated to developing advanced immunotherapies aimed at revolutionizing cancer treatment. Leveraging its proprietary platform that optimizes the immune system's ability to detect and eradicate tumor cells, Indaptus is committed to enhancing treatment effectiveness and patient outcomes. The firm's diverse pipeline of clinical candidates targets significant unmet needs in oncology, positioning it for strong growth amidst a competitive landscape. With a focus on scientific advancement and collaborations with premier research institutions, Indaptus is well-equipped to become a transformative player in the biopharmaceutical industry.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?